Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

NCT01032850 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped Low accrual rate

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Sorafenib & Capecitabine

Sponsor

New Mexico Cancer Research Alliance

Collaborators

[object Object]